Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx 'Reformulation' In Herbal Sleep Aid Gives FDA A Nightmare

Executive Summary

FDA inspects Belmora's website and product labeling in March and issues a warning letter that firm’s Elavil OTC Sleep Aid is an unapproved new drug with inadequate directions for its intended use.

You may also be interested in...



Spiked Supplement Holiday Deliveries Stopped By Import Examinations

FDA alerts consumers and health care providers to 13 products found in examinations of international mail shipments to contain sildenafil and one with the banned drug sibutramine.

Drug Product Recalls in 2013 Categorized by Problem Area

This comprehensive table provides key facts at a glance for every one of the 1,276 drug recalls FDA reported last year, grouped into seven main problem areas. For each recall, it says what product was recalled and how much of it was recalled, what company manufactured it and recalled it, how seriously FDA rated the health threat the recalled product posed, and what reason the company gave for recalling the product.

‘Undeniable Truth’ For US FDA Supplement Programs Director: 'So Much Noncompliance'

ODS Director Steven Tave says violative manufacturing processes and products remain common not because FDA isn’t enforcing its regulations. “I applaud those who stand behind their products, but can you stand with the same conviction behind every product on the market?” he said at regulatory summit organized by trade groups.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel